Article
Current therapy for hepatitis C.
International journal of colorectal disease - 1 Apr 2007
Friedrich-Rust Mireen, Zeuzem Stefan, Sarrazin Christoph
Abstract excerpt
INTRODUCTION: Pegylated interferon alfa in combination with ribavirin has been established as standard therapy for chronic hepatitis C virus (HCV) infection with sustained virologic response rates of 54-63%. The duration of therapy depends on the HCV genotype with currently 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3. RESULTS AND DISCUSSION: The probability of sustained virologic response is very...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
